Citations

Clear

101 citation(s) found for "Ng, Chee H".

A Three-Day Postoperative Recovery Pathway After Robotic Pancreatoduodenectomy
Yu, Stephanie, Cheung, Dillon, Stucky, Chee-Chee, Tan, Po Hong, Sanford, Dominic E. , Bold, Rick J., Wasif, Nabil , Fong, Zhi Ven

Mayo Clinic

Annals of Surgery Open | November 4, 2026 | Volume: 7 | Issue: 4 | Pages: e722

10.1097/as9.0000000000000722 Get It

Background and Objective: Enhanced Recovery After Surgery (ERAS) protocols and minimally invasive techniques may accelerate recovery following pancreatoduodenectomy (PD). We evaluated the feasibility and safety of combining minimally invasive PD with a tailored ERAS protocol on post-PD outcomes and quality of life (QoL). Methods: Patients undergoing PD from 2023 to 2025 were identified. The 2019 ERAS Society recommendations for PD were implemented. Multivariable regression was used for adjusted analyses, with performance assessed by area under the curve (AUC) and Brier scores. QoL was measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 and PAN-26 modules. Results: Of 113 patients, 67.3% underwent robotic and 32.7% open PD with comparable baseline characteristics. Postoperative day (POD) 3 discharge occurred in 34.2% of robotic cases and none of the open cases ( P < 0.001). POD 3 discharge correlated with fewer cumulative 90-day hospital days (3 days vs 5 days, P < 0.001) and overall complications (42.3% vs 68.0%, P = 0.031), without differences in major complications, readmissions, or 90-day mortality. POD 1 drain fluid amylase (DFA) was lower in POD 3 discharges (40 U/L vs 808 U/L, P = 0.014), and DFA <300 U/L identified patients likely to achieve POD 3 discharge without adverse events with good discrimination and calibration (AUC = 0.843; Brier = 0.120). Early discharge was associated with improved overall QoL (+5.6 vs −15.0; P = 0.006) without differences in pain scores (+8.3 vs +12.5; P = 0.240). Conclusions: ERAS protocols with minimally invasive PD facilitated safe POD 3 discharge. POD 1 DFA <300 U/L may help identify patients safe for early discharge without compromising outcomes or QoL.
Mind the Gap: How Velopharyngeal Gap Size Influences Consonant Accuracy
Snodgrass, Taylor , Perry, Jamie L , Sitzman, Thomas J , Chee-Williams, Jessica L

Mayo Clinic

The Cleft Palate Craniofacial Journal | October 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10556656261502095 | PMID 42931551 Get It

Objective Assess if velopharyngeal gap size during speech is associated with consonant accuracy and whether hypernasality severity and compensatory misarticulation errors (CMAs) mediate this relationship. Design Cross-sectional. Setting Metropolitan hospital. Participants Eighty-one patients undergoing assessment for velopharyngeal insufficiency (VPI). Assessment(s) Each patient completed a preoperative magnetic resonance imaging protocol during sustained /i/ production and a perceptual speech evaluation. Velopharyngeal gap size was measured in millimeters. Hypernasality was rated using the Cleft Audit Protocol for Speech-Augmented-Americleft Modification. Percent consonants correct (PCC) and percent of CMAs used were derived from transcriptions of the American English sentence or phrase sample. Main Outcome Measure(s) A generalized structural equation model was used to examine whether velopharyngeal gap size is associated with PCC indirectly through hypernasality severity and CMA use. Results Larger velopharyngeal gap sizes were associated with more severe hypernasality ( P < .001), greater hypernasality severity was associated with increased CMA use ( P < .001), and greater CMA use was associated with lower PCC ( P < .001). Velopharyngeal gap size was not directly associated with PCC ( P = .400). However, the full indirect pathway from gap size to PCC through hypernasality severity and CMA use was significant ( P = .001); gap size was significantly associated with PCC when accounting for both direct and indirect pathways combined ( P = .005). Conclusions These findings suggest hypernasality severity is the key mediator between gap size and speech accuracy. Patients with more severe hypernasality may benefit from timely surgical remediation of VPI to increase overall consonant accuracy.
The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer
Lu, Patricia G , Stucky, Chee-Chee, Potter, Alexandra, Yang, Chi‐Fu Jeffrey, Pannala, Rahul , Wasif, Nabil , Anderson, Michelle A., Chang, Yu‐Hui H., Lu, Patricia Gina , Chang, Yu‐Hui , Potter, Alexandra L. , Linderman, George C. , Yang, Chi‐Fu Jeffrey , Fong, Zhi Ven

Mayo Clinic

Journal of Surgical Oncology | August 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jso.70361 | PMID 42590794 Get It

ABSTRACT Background Post‐pancreatectomy exocrine insufficiency is common after resection for pancreatic cancer and requires pancreatic enzyme replacement therapy (PERT). We sought to determine the out‐of‐pocket cost of PERT and the association between PERT and survival. Methods The SEER‐linked Medicare database was queried for patients with pancreatic cancer who underwent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) from 2010 to 2019. Cumulative out‐of‐pocket costs were calculated and stratified by procedure and radiation. Results 11,854 Medicare beneficiaries with resected pancreatic cancer were identified, 4,653 (39%) required PERT and 7,201 (61%) did not. Median age was 73.0, 50.6% were female and 83.6% White. 25.9% underwent DP and 74.1% underwent PD; 7% received neoadjuvant radiation while 23.5% received adjuvant radiation. Logistic regression demonstrated that female sex (OR 1.25, 95% CI 1.16‐1.35, p < 0.001), neoadjuvant radiation (OR 1.93, 95% CI 1.67‐2.24, p < 0.001), and PD (OR 2.45, 95% CI 2.23‐2.7, p < 0.001) were risk factors for requiring PERT. Patients without subsidies who underwent DP paid a cumulative $4,736 out‐of‐pocket for PERT after 5 years, those who underwent PD paid $5,601 out‐of‐pocket. Conclusions Nearly 40% of Medicare beneficiaries took PERT after resection for pancreatic cancer and paid thousands in out‐of‐pocket costs. While a conservative estimate, these findings highlight the importance of addressing this financial burden to patients.
Inconsistencies in Clinical Reporting of Nasopharyngoscopy for Evaluating Velopharyngeal Closure: A Multisite Study
Chee-Williams, Jessica L. , Stewart, Emma K. , Sitzman, Thomas J. , Perry, J. Lyman, Perry, Jamie L. , Perry, Jamie L , Sitzman, Thomas J , Chee-Williams, Jessica L

Mayo Clinic

American Journal of Speech-Language Pathology | June 5, 2026 | Volume: 35 | Issue: 4 | Pages: 1744-1755

10.1044/2026_ajslp-25-00622 | PMID 42247245 Get It

Purpose: Nasopharyngoscopy is an imaging method used to visualize the velopharyngeal mechanism. To quantify the movement of the mechanism during speech, an international working group recommended standardized rating guidelines. While these guidelines are widely cited in research, the extent to which cleft teams apply them in a clinical setting is unclear. Method: This cross-sectional study examined clinical nasopharyngoscopy reports from 11 cleft teams in North America. Descriptive statistics were used to summarize the proportion of reports that included ratings for the extent of velar movement, left and right lateral pharyngeal wall movement, gap size, and a surgical recommendation. Fisher's exact and chi-square tests were used to assess differences in reporting by cleft team and whether the inclusion of quantitative ratings was associated with a surgical recommendation being included. Results: A total of 188 nasopharyngoscopy reports were included. The extent of velar movement was reported in 68% ( n = 127) of reports, the left and right lateral pharyngeal wall movement was reported in 38% ( n = 71), and the size of the gap was reported in 70% ( n = 132). Only 34% ( n = 63) of reports included all three quantitative ratings. Inclusion of all three quantitative ratings varied significantly ( p < .001) across teams. Teams either never included all the ratings ( n = 4/11) or inconsistently included all ratings ( n = 7/11). Conclusions: Findings suggest that what is documented clinically in nasopharyngoscopy reports varies both within and across teams. To achieve more consistent reporting within individual teams, providers may consider implementing standardized clinical templates. To achieve consistency across teams, these findings suggest a need for renewed efforts at developing consensus on the nasopharyngoscopy elements important to clinicians.
De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis
Miller, R., Tan, Po Hong, Saleeb, Andrew, Stucky, Chee-Chee, Bagaria, Sanjay P, Gabriel, Emmanuel , Grotz, Travis E. , Wasif, Nabil , Miller, Max , Thompson, Emily , Miller, Richard Max , Thompson, Emily R , Grotz, Travis E , Gabriel, Emmanuel M , Saleeb, Andrew G. , Thompson, Emily R., Fong, Zhi Ven , Bagaria, Sanjay P.

Mayo Clinic

Journal of Surgical Oncology | April 30, 2026 | Volume: 134 | Issue: 1 | Pages: 91-100

10.1002/jso.70274 | PMID 42057320 Get It

ABSTRACT Background and Objectives NCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1–2 cm tumors remains controversial. This study compared long‐term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1–2 cm aNETs. Methods Patients with pathologically confirmed 1–2 cm aNETs treated at three Mayo Clinic sites (1972–2024) were included. Primary outcomes were recurrence and all‐cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy. Results Sixty‐five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow‐up of 6.25 years (IQR 2.44–12.63). Conclusions Among patients with 1–2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.
The Association of Extended Venous Thromboembolism Prophylaxis and Venous Thromboembolism After Cancer Surgery
Tan, Po Hong, Lillemoe, Keith D., Stucky, Chee-Chee, Brady, Justin T., Pockaj, Barbara A. , Cronin, Patricia, Potter, Alexandra L. , Yang, Chi-Fu Jeffrey, Mavros, Michail N., Fagenholz, Peter J. , Kastrinakis, William V., Poruk, Katherine E. , Wasif, Nabil , Qadan, M., Pockaj, Barbara, Poruk, Katherine, Fong, Zhi Ven , Lillemoe, Keith D. , Stucky, Chee-Chee, Brady, Justin T. , Cronin, Patricia, Linderman, George C. , Yang, Chi‐Fu Jeffrey , Mavros, Michail N. , Thiels, Cornelius A. , Habermann, Elizabeth B. , Chang, Yu‐Hui , Qadan, Motaz

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 19, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.7128 | PMID 41911913 Get It

Background: ASCO recommends extended venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) following cancer surgery. However, these recommendations were based on trials using routine venography, which detects asymptomatic VTEs, and real-life efficacy is not well studied. We aimed to assess the association of extended VTE prophylaxis with the incidence of clinically significant VTE after elective cancer surgery. Patients and Methods: In this retrospective, population-based cohort study, we identified patients who underwent surgical resection for lung, breast, esophageal, gastric, pancreas, and colon cancer from 2010 to 2017 using the SEER–Medicare linked dataset. Patients were divided into 1 of 2 main groups for comparative analyses: those who received extended VTE prophylaxis after cancer surgery and those who did not. Patients who received extended VTE prophylaxis after cancer surgery were identified as those prescribed prophylactic doses of LMWH or a DOAC within 7 days of discharge, as captured in Medicare Part D files. Results: A total of 113,739 Medicare beneficiaries were identified, of whom 1,570 (1.4%) received extended VTE prophylaxis. There was a year-over-year increase in the use of extended VTE prophylaxis during the study period, rising from 0.6% in 2010 to 3.3% in 2017. The overall incidence of VTE was 1.6% at 1 month, 4.3% at 6 months, 5.7% at 12 months, with significant differences observed across cancer types ( P <.001). However, patients who received extended VTE prophylaxis had a higher 1-year cumulative incidence of postoperative VTE compared with those who did not (11.4% vs 5.3%; P <.001), an association that was consistent across cancer sites. In adjusted analyses, extended VTE prophylaxis was independently associated with an increased risk of VTE (hazard ratio, 1.6; 95% CI, 1.3–2.0; P <.001). Extended prophylaxis was also associated with a higher 1-year incidence of bleeding events compared with patients who did not receive prophylaxis (12.0% vs 8.5%; P <.001). Conclusions: The utilization of extended VTE prophylaxis after cancer surgery remains low, although it has increased every year. Paradoxically, patients who received extended VTE prophylaxis had higher incidences of clinically significant VTE and bleeding compared with those who did not, likely reflecting patient selection and surveillance bias after surgery. In light of these findings, national guidelines recommending postoperative extended VTE prophylaxis, and its use as a surrogate for quality of care, should continue to be re-examined.
Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
Tan, Po Hong, Thiels, Cornelius A., Poruk, Katherine E. , Miller, R., Hor, Hoe Yan , Tu, Melody Pi Yin , Huyser, Michelle R., Stucky, Chee-Chee, Wasif, Nabil , Bold, Richard J. , Smoot, R., Starlinger, Patrick P., Warner, Susanne G., Kendrick, M., Stauffer, John A., Truty, M., Fong, Zhi Ven, _, _, Poruk, Katherine, Miller, Richard Max, Thiels, Cornelius A. , Stucky, Chee‐Chee , Starlinger, Patrick , Warner, Susanne G. , Kendrick, Michael L. , Stauffer, John , Truty, Mark J. , Fong, Zhi Ven

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 27-33

10.6004/jnccn.2025.7097 | PMID 41671431 Get It

Background: Upfront resectable pancreatic ductal adenocarcinoma (PDAC) is defined by the NCCN as disease with ≤180° portomesenteric vein (PMV) abutment. However, the clinical significance of PMV abutment in this cohort remains unexplored, and we sought to investigate its impact. Methods: This multi-institutional study included patients who underwent pancreatoduodenectomy (PD) for upfront resectable PDAC from 2002 to 2023. Patients with PDAC with ≤180° PMV abutment were compared with those without. Overall survival (OS) was compared and stratified based on whether patients underwent upfront surgery or neoadjuvant therapy (NAT). Results: Among 1,446 patients included, 521 (36.0%) had PMV abutment. Median OS for patients with PMV abutment was 28.8 months compared with 31.2 months for those without ( P =.17). In a stratified analysis of patients who underwent upfront surgery, patients with PMV abutment had worse OS (19.2 vs 27.6 months; P <.05) and lower R0 resection rates (63.1% vs 87.2%; P <.05) compared with those without. However, in patients who underwent NAT, this difference in R0 resection rate was not observed (91.4% vs 94.0%, respectively; P =.27). Furthermore, there was no significant difference in median OS with NAT (42.5 vs 51.6 months, respectively; P =.48). Conclusions: In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
Improving Intraoperative Parathyroid Hormone Monitoring with a Multidisciplinary Checklist: A Quality Improvement Initiative
Swisher, Austin R. , Hintze, Justin M. , Stucky, Chee‐Chee , Entezami, Payam , Hinni, Michael L., Cronin, Patricia A. , Hintze, Justin , Swisher, Austin R , Chang, Brent A.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 26, 2025 | Volume: 174 | Issue: 2 | Pages: 561-569

10.1002/ohn.70081 | PMID 41451691 Get It

Abstract Objective Intraoperative parathyroid hormone (ioPTH) monitoring is crucial during parathyroid surgery to ensure chemical cure. However, delays in processing can prolong operative times. This study evaluates the effectiveness of a checklist to expedite ioPTH assay processes. Methods A multidisciplinary checklist was developed to standardize ioPTH collection and workflow. Thirty patients treated with use of the checklist were prospectively studied, while 30 patients treated without use of the checklist were retrospectively reviewed. Time intervals for post–15‐minute ioPTH assay results were compared. Results Thirty age‐ and sex‐matched patients were included in each group (n = 60) involving 5 surgeons. The intervention and control group had a mean baseline PTH of 140.9 and 130.3 pg/mL and a post–15‐minute ioPTH of 69.6 and 52.0 pg/mL, respectively. The mean time from sample collection to the post–15‐minute ioPTH assay result was significantly reduced in the intervention as compared to the control group (22.2 vs 33.3 minutes; P < .01). The proportional operative time spent awaiting ioPTH assay results was also reduced (24.4 vs 34.1%; P < .01). In subgroup analysis, a significant difference in the total operative time was found in adenomatous disease (68.0 vs 92.2 minutes, P < .05) but not four‐gland hyperplasia (119.3 vs 142.3 minutes). Discussion The implementation of a simple intraoperative checklist effectively reduces the overall ioPTH assay processing time, creating a more efficient surgical workflow. It is low‐cost and requires minimal additional resources. Implications for Practice This quality improvement intervention holds promise for broader adoption in parathyroid surgery to reduce delays and optimize patient care.
Genomic and transcriptomic landscape of extranodal marginal zone lymphoma
Lossos, Izidore S., Biral, Leo, Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer, Lossos, Izidore S., Biral, Leonardo P. A. , Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1761-1761

10.1182/blood-2025-1761 Get It

Abstract Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin B-cell lymphoma accounting for 7-10% of lymphoma diagnoses. Extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT) is the most common subtype (61%) of MZL. While the mutational landscape, chromosomal aberrations and transcriptome of nodal and splenic MZL have been extensively evaluated, the mutational landscape of EMZL has only been evaluated in a small number of patients and mainly by targeted sequencing. Consequently, the comprehensive genomic landscape of EMZL remains largely uncharacterized. Herein, we performed whole exome sequencing followed by targeted sequencing of potential tumor driver genes, copy number and/or RNA transcriptome analyses in 165 patients with pretreatment EMZL tumors involving 16 anatomic locations. All samples were collected and underwent expert review as part of the Atlas of Blood Cancer Genomes consortium. The most common anatomic locations were ocular adnexa (OAMZL) (n=35), gastric (n=25, including 6 positive for Helicobacter pylori), salivary glands (n=25), and lungs (n=24). Using common criteria for variant mutation calling and significant focal copy number (CN), we identified 1218 variants (1030 missense and 188 truncation mutations) across 174 genes and 2837 CN focal alterations (1614 copy gains and 1223 copy number losses). Of these genes, 44 and 11 were mutated in &gt;5% and &gt;10% of specimens, respectively. We detected variants identified previously by targeted sequencing in EMZL from different locations (e.g. TNFAIP3 (A20) (12%), TBL1XR1 (13%), SPEN (10%), CARD11 (7%), TET2 (7%) and CREBBP (6%)). We detected mutations in KLF2 (10 mutations in 8 EMZL patients) and PTPRD (7 mutations in 7 EMZL patients) that were previously suggested to be specific for splenic and nodal MZL, respectively. We also detected variants not previously reported in EMZL, including a transcriptional factor ZEB2, LRP1B,and others. The most frequently mutated gene in our study (25% of tumors) was IGLL5. Some mutations were limited to specific locations (e.g. ZEB2 mutations seen exclusively in gastric and salivary gland EMZL), while most were observed across all anatomic locations. There was no association between specific mutations and clonal IGHV, in contrast to previous reports. Using Enrichr tool, we observed enrichment of mutations in genes belonging to the B cell receptor activation, NOTCH signaling, Wnt-beta catenin signaling, NF-kB signaling , PI3K AKT signaling, DNA repair and other pathways. Chromosomal and copy number changes were also commonly observed including previously reported trisomy of chromosomes 3 and 18. Combining DNA mutations and CN alterations, the number of genetic lesions per tumor sample in the 174 mutated genes ranged from 0 to 95, with an average load of 17 lesions per case. RNA sequencing was successful in 159 EMZL tumors from 16 distinct anatomic locations. Unsupervised clustering using all genes with a median log2-normalized gene expression value greater than 5 and a standard deviation greater than 1 (1323 genes) demonstrated that the majority of gastric EMZL with and without H. pylori infections clustered together on 2 dendrograms as did most of the samples of OAMZL. Since the clustering could be forced by organ-specific and not tumor-specific gene expression, we next focused on the expression of the 345 genes from the LM22 matrix that passed our transcriptomic row filtering. Unsupervised clustering resulted in clustering of most gastric EMZL irrespective of H. pylori positivity together in the same dendrogram branch, accompanied by few additional EMZL from other anatomic locations. Most of the EMZL samples from other locations did not show preferential co-clustering together. On comparison of gene expression between gastric and OAMZL, there was enrichment of the B-cell receptor signaling pathway, B-cell activation, B-cell naïve and B-cell memory cells, B-cell proliferation and NF-kB signaling in the latter. Immune microenvironment analysis showed a statistically significant increase in resting mast cells and decrease in M1 macrophages in gastric EMZL and increase in regulatory T cells in salivary EMZL. The broad genomic studies reported here underscore the biological similarity of EMZL across anatomical sites with the potential exceptions of gastric EMZL (regardless of H. Pylori status). These data provide valuable genomic and transcriptomic resources to inform future diagnostic and therapeutic strategies.
What is the Patient Compliance Rate for Nasopharyngoscopy as Documented in Clinical Reports?
Chee-Williams, Jessica L. , Stewart, Emma K. , Sitzman, Thomas J. , Perry, Jamie L. , Sitzman, Thomas J , Chee-Williams, Jessica L , Perry, Jamie L

Mayo Clinic

The Cleft Palate Craniofacial Journal | November 28, 2025 | Volume: 63 | Issue: 9 | Pages: 3053-3058

10.1177/10556656251400414 | PMID 41313313 Get It

Objective Assess the patient compliance rate for nasopharyngoscopy as documented in clinical reports. Design Cross-sectional. Setting Thirteen cleft teams in North America. Patients Patients aged 3 to 21 years old with a repaired cleft palate. Interventions Nasopharyngoscopy. Main Outcome Measure Patient compliance rate for nasopharyngoscopy. Results Patient compliance was documented in 128 of 158 reports (81%). Of the 128 reports, patient compliance was reported as “good/excellent” in 65% (n = 83), “marginal/fair” across 10% (n = 13), “poor” in 16% (n = 20), and “other” in 9% (n = 12). Patients with “poor” compliance had lower rates of documented imaging ratings, however 55% (n = 11) of reports included a surgical recommendation. Conclusions Among children completing nasopharyngoscopy for velopharyngeal insufficiency surgery planning, at least one-fourth of reports indicate significant compliance issues that limits velopharyngeal port imaging. These findings suggest that some cleft teams and surgeons may be proceeding with surgical management of velopharyngeal insufficiency without adequate visualization or ratings of velopharyngeal anatomy.